Navigation Links
ViroPharma To Acquire Lev Pharmaceuticals
Date:7/15/2008

investors and security holders to read the proxy statement/prospectus regarding the proposed merger when it becomes available because it will contain important information.

You may obtain copies of all documents filed with the SEC regarding this transaction, free of charge, at the SEC's website ( http://www.sec.gov ). You may also obtain these documents, free of charge, from ViroPharma's website ( http://www.viropharma.com ) under the tab "Investors" and then under the item "SEC Filings". You may also obtain these documents, free of charge, from Lev's website ( http://www.levpharma.com ) under the tab "Investor Relations" and then under the heading "SEC Filings."

Proxy Solicitation

ViroPharma, Lev and their respective directors, executive officers and certain other members of management and employees may be soliciting proxies from Lev stockholders in favor of the merger. Information regarding the persons who may, under the rules of the SEC, be considered participants in the solicitation of the Lev stockholders in connection with the proposed merger will be set forth in the proxy statement/prospectus when it is filed with the SEC. You can find information about ViroPharma's executive officers and directors in its definitive proxy statement filed with the SEC on April 11, 2008. You can find information about Lev's executive officers and directors in definitive proxy statement filed with the SEC on April 16, 2008. You can obtain free copies of these documents from ViroPharma and Lev using the contact information above.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... September 2, 2015 BioLight ... or the "Company"), a firm that invests in, ... cancer diagnostics, announced today that presentations highlighting its ... be delivered at the Ophthalmology Futures European Forum ... of Cataract & Refractive Surgeons ("ESCRS"), both taking ...
(Date:9/2/2015)... ... ... Temarry Recycling's new $100,000 waste to energy capital project ... to contribute to the sustainability of our natural resources. , Waste to Energy ... operating at their Mexico facility, Recicladora Temarry, for the last 7 years. While ...
(Date:9/1/2015)... CHICAGO , Sept. 1, 2015 The ... of Intent (LOI) for its Discovery Research Grant program. ... 2015 at 12:00 noon CDT. Discovery ... projects with the potential to change current diagnostic or ... These grants specifically encourage novel research at its earliest ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... antibodies, announced today that the National Institutes of Health (NIH) has awarded the ... be administered by the NIH’s National Institute of Diabetes and Digestive and Kidney ...
Breaking Biology Technology:Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3
... ... Leading Virtual Data Room To Share Due Diligence Documents , ... Los Gatos, CA (PRWEB) September 16, 2009 ... been adopted by a number of pharmaceutical, biopharmaceutical and biotech research and development companies ...
... , Collaboration with Biomodels facilitates development of novel ... Avaxia Biologics, Inc., a biotechnology company developing oral antibodies for ... has been awarded a Phase I SBIR grant from the National ... a novel antibody therapeutic for oral mucositis. , , ...
... Sealers, cleaners, and ... , ... 16, 2009 - Tile Media Properties (TMP), best known for The Tile Doctor brand and ... The 10 year-old Atlanta-based company receives millions of unique visitors annually and is well-recognized as ...
Cached Biology Technology:Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering 2Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering 3Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 2Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 3The Tile Doctor Launches Inaugural Product Line 2The Tile Doctor Launches Inaugural Product Line 3
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Institute scientist Matthias von Herrath, M.D., a world leader in ... seeing his discoveries translated into new therapies to better treat ... may soon get his chance as head of a new ... in 2012 by Novo Nordisk, a global healthcare company specializing ...
... a huge tsunami inundated paddy fields in Japan with salty ... Following a Japan-UK research collaboration, a new method for marker ... takes to isolate new traits such as salt tolerance. Details ... Nature Biotechnology on Sunday so they can be ...
... 2 emissions due to human activities enters the world,s ... water,s acidity, which may significantly reduce the calcification rate of ... which human activities have raised the surface level of acidity, ... it varies naturally from one season and one year to ...
Cached Biology News:La Jolla Institute scientist takes quest to conquer Type 1 diabetes to the next level 2Science to help rice growers affected by Japan's tsunami 2Unprecedented, man-made trends in ocean's acidity 2Unprecedented, man-made trends in ocean's acidity 3
... optically clear polystyrene formulation , High antibody-binding ... , Plates are certified for performance ... , Eight-well strips fit snugly in ... in use even if turned upside down ...
...
... StabilZyme SELECT Stabilizer is an aqueous ... and other non-toxic stabilizing chemicals in a ... contains a combination of 0.02% methylisothiazolone and ... SELECT Stabilizer is a diluent and stabilizer ...
... is a bovine protein-free alternative to StabilCoat ... solution that contains non-toxic chemicals in a ... - 7.2, and does not contain a ... of antibodies and other biomolecules that are ...
Biology Products: